Product review · Updated September 30, 2026
Clinique Advanced Clearing Gel: one-hour blemish size is not a blackhead result
The Advanced gel’s 31-woman clinical summary belongs to a different product record from the older gel’s 118-woman consumer account.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
Clinique Acne Solutions Clinical Advanced Clearing Gel makes a precise-sounding promise: a blemish starts to look smaller in one hour. Its footnote identifies 31 women after a single use. That is more detail than a general clearing slogan, but it still describes a particular visible-size endpoint rather than the clearance of blackheads.
The official Advanced product and its US label are reviewed together. A separately named older Clinical Clearing Gel has other claims, participants and ingredients. This review keeps those accounts apart so that the older gel’s larger consumer group or prescription comparison does not become evidence for the current Advanced product.
In this article
Advanced is part of the exact product identity
The current manufacturer page names Acne Solutions Clinical Advanced Clearing Gel and describes a hydro-gel with 2% salicylic acid. It displays a 0.68-fluid-ounce size. The March 2025 US label identifies a 20 mL principal panel and the same Advanced name, with an acne-treatment purpose.
The word Advanced matters because the older official page omits it and carries another product account. Shared branding is not enough to merge the two. The label and current page provide useful identity evidence, including the current ingredient-list identifier. They do not inspect a reader’s package, establish a stock transition or prove that every item sold under a similar name has this record’s base.
The footnote concerns the size of a blemish
The Advanced claim says a blemish begins to look smaller in one hour. Its footnote attributes the statement to clinical testing on 31 women after the product was used once. The summary does not identify blackheads as the measured finding or supply the full methods, comparison conditions or magnitude of change.
AAD’s blackhead description identifies an open comedo, which is a particular acne finding. That context does not retest Clinique’s gel. It explains why a blemish-size statement cannot simply be renamed a blackhead result. The visible-pores guide gives further background for keeping a product endpoint and the wider appearance of pores distinct, without turning one-hour wording into a personal expectation.
The broader clearing story has another role
The Advanced description says the 2% salicylic formula targets pore-clogging oil and dead skin cells, helps visibly clear breakouts and helps prevent new ones. These are manufacturer claims about the product’s role. They are broader than the specific one-hour size endpoint attached to the 31-woman footnote.
The US label separately gives an acne-treatment use. Neither passage supplies a quantified result for every feature in the broader narrative. It would be misleading to assume that the one-hour summary validates all the prevention and pore language too. Keeping the general description, label purpose and reported endpoint separate makes the gel’s actual evidence easier to follow.
The older gel’s prescription comparison stays older
The older Clinical Clearing Gel page describes prescription-strength performance and says results were as good as a topical acne prescription in a 12-week clinical study. The examined summary does not provide the full report or enough comparison detail to establish equivalence independently. Its wording is attributed to that older product.
The account cannot be transferred to the Advanced gel because the brand and much of the name are similar. It also does not establish prescription status for either item. The meaningful point is documentary: the older page makes a different comparison claim from the Advanced page’s one-hour blemish-size statement. Keeping the exact name beside each avoids presenting two separate summaries as one stronger clinical account.
One hundred eighteen women belong to an overnight consumer account
The older page separately says 95% reported clearer-looking skin overnight. Its footnote describes consumer testing on 118 women after two uses. That is a different group, evidence description and result from the Advanced gel’s clinical summary involving 31 women and the visible size of a blemish.
The consumer percentage is not a missing denominator for the Advanced claim, and the two uses are study context rather than instructions offered here. The progress-records guide discusses how changes can be described specifically. In this case, clarity comes from retaining the separate product, group and endpoint, rather than treating the larger number as reassurance about a result it did not describe.
The declarations confirm another version boundary
The Advanced product list carries ILN52924, matching the identifier on the posted label. The older page carries ILN52627 and names benzalkonium chloride and alcohol within its different inactive list. These are exact declaration details, not evidence that one version clears pores better or feels gentler.
Both product pages qualify their ingredient lists with package-change language. FDA’s label guidance also acknowledges product and labeling changes. This helps explain why older and newer claims cannot be linked merely through the brand name. The declarations identify separate records; they do not settle which bottle a reader has or attribute a clinical result to an individual component.
A precise summary still needs a precise conclusion
The Advanced record provides a useful participant count and named visible-size endpoint. Its acne label adds product identity and dryness limitations. No application or combination advice is reproduced. The available summary remains a manufacturer account, without the full clinical report needed to assess its size of effect or relevance to an individual.
For other evidence questions, see the Paula’s Choice review and SkinCeuticals review, alongside the format comparison. The conclusion here is specific: a one-hour blemish-size statement belongs to the Advanced gel’s 31-woman account. It does not acquire a blackhead result, a prescription-equivalence finding or the older product’s consumer evidence simply by sharing a familiar name.
Sources behind this reading
- Clinique Acne Solutions Clinical Advanced Clearing Gel: current US product and 31-woman endpoint ↗Official manufacturer product record; exact market and selected claim scope · Checked September 30, 2026
- Clinique Advanced Clearing Gel: March 3, 2025 US label ↗Official posted US product-label record; exact date, NDC and version scope · Checked September 30, 2026
- Clinique Clinical Clearing Gel: separately named older product and 118-woman account ↗Official manufacturer product record; exact market and selected claim scope · Checked September 30, 2026
- American Academy of Dermatology: Acne signs and symptoms ↗Clinical category explanations; not an image-based assessment · Checked September 30, 2026
- FDA: reading an OTC Drug Facts label ↗Regulator consumer labeling guidance · Checked September 30, 2026